Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

TRML

Tourmaline Bio Inc

Nov 29 • 04:00PM ET

18.42

Dollar change +0.47
Percentage change 2.62	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-17.93	Insider Own	34.41%	Shs Outstand	20.34M	Perf Week	4.72%
Market Cap	374.66M	Forward P/E	-	EPS next Y	-3.35	Insider Trans	-2.79%	Shs Float	13.34M	Perf Month	24.04%
Income	-74.77M	PEG	-	EPS next Q	-1.03	Inst Own	17.42%	Short Float / Ratio	3.05% / 10.96	Perf Quarter	-34.91%
Sales	0.00M	P/S	-	EPS this Y	81.98%	Inst Trans	-9.97%	Short Interest	0.41M	Perf Half Y	-30.49%
Book/sh	34.88	P/B	0.53	EPS next Y	0.20%	ROA	-39.35%	Target Price	52.67	Perf Year	25.31%
Cash/sh	7.49	P/C	2.46	EPS next 5Y	-	ROE	-41.64%	52W Range	8.90 - 32.90	Perf YTD	80.59%
Dividend	15.12	P/FCF	-	EPS past 5Y	-	ROI	-50.23%	52W High	-44.01%	Beta	2.25
Dividend %	82.07%	Quick Ratio	15.41	Sales past 5Y	0.00%	Gross Margin	-	52W Low	106.97%	ATR	1.77
Employees	129	Current Ratio	15.41	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	50.72	Volatility	9.09% 9.83%
Optionable	No	Debt/Eq	0.01	EPS Q/Q	20.65%	Profit Margin	-	Rel Volume	0.83	Prev Close	17.95
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	37.09K	Price	18.42
Recom	1.00	SMA20	8.69%	SMA50	-13.52%	SMA200	-24.32%	Volume	30,615	Change	2.62%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-17-23	Initiated	Truist	Buy	$43
Oct-31-23	Initiated	Guggenheim	Buy	$50
Oct-25-23	Initiated	Piper Sandler	Overweight	$65
Oct-20-22	Initiated	H.C. Wainwright	Buy	$18
Jul-05-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$20 → $8

Nov-01-23 08:00AM	Tourmaline Bio to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-26-23 09:02PM	CEO Sandeep Kulkarni Buys 9650 Shares of Tourmaline Bio Inc (GuruFocus.com) +5.83%
Oct-19-23 05:37PM	Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million (GlobeNewswire)
Oct-17-23 05:47PM	Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio (GlobeNewswire) -6.00%
Oct-06-23 05:09PM	Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio (GlobeNewswire)
08:30AM	Loading…
Oct-04-23 08:30AM	New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics (GlobeNewswire)
Jun-22-23 07:30AM	Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement (GlobeNewswire) +22.73%
May-26-23 07:00AM	Talaris Therapeutics Announces Leadership Transition (GlobeNewswire)
May-20-23 08:18AM	Talaris Therapeutics, Inc. (NASDAQ:TALS) most popular amongst private equity firms who own 34% of the shares, institutions hold 30% (Simply Wall St.)
Feb-16-23 03:10PM	Wellesley biotech cuts one-third of staff, explores sale (American City Business Journals) +24.05%
07:00AM	Talaris Therapeutics Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan (GlobeNewswire)
Dec-25-22 09:25AM	We Think Talaris Therapeutics (NASDAQ:TALS) Needs To Drive Business Growth Carefully (Simply Wall St.)
Nov-22-22 07:00AM	Talaris Therapeutics to Participate at the 5th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-10-22 07:00AM	Talaris Therapeutics Announces Third Quarter Financial Results and Corporate Update (GlobeNewswire) +6.99%
Nov-07-22 07:00AM	Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance (GlobeNewswire)
11:28AM	Loading…
Oct-21-22 11:28AM	Talaris (TALS) Down on Patient Death From Renal Transplant Study (Zacks)
Oct-20-22 02:27PM	HC Wainwright Says Talaris' Technology Unprecedented In Cell Therapy Space (Benzinga) -43.39%
10:26AM	Talaris Therapeutics Reports Patient Death In Late-Stage Trial Of Experimental Drug For Graft vs Host Disease (Benzinga)
08:24AM	Talaris Therapeutics' stock falls 21% after reporting patient death in clinical trial (MarketWatch)
07:00AM	Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial (GlobeNewswire)
Oct-17-22 07:00AM	Talaris Therapeutics Announces Upcoming Presentations at American Society of Nephrology Annual Meeting (GlobeNewswire) +6.96%
Oct-04-22 07:00AM	Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa (GlobeNewswire)
Sep-21-22 07:00AM	Talaris Therapeutics to Present at William Blairs Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event (GlobeNewswire)
Sep-06-22 07:00AM	Talaris Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire) +6.19%
Aug-15-22 07:00AM	Talaris Therapeutics Announces Second Quarter Financial Results and Corporate Update (GlobeNewswire)
Jul-18-22 09:47AM	We Think Talaris Therapeutics (NASDAQ:TALS) Can Afford To Drive Business Growth (Simply Wall St.)
Jun-30-22 07:00AM	Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update (GlobeNewswire) -36.75%
Jun-07-22 04:01PM	Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022 (GlobeNewswire)
Jun-01-22 07:00AM	Talaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) and Provide a Data Update from its Phase 3 FREEDOM-1 Study (GlobeNewswire)
May-31-22 07:00AM	Talaris Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire) +16.35%
04:01PM	Loading…
May-17-22 04:01PM	Talaris Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +35.93%
07:00AM	Talaris Therapeutics Announces Changes to Board of Directors (GlobeNewswire)
May-12-22 04:01PM	Talaris Therapeutics Announces First Quarter Financial Results and Corporate Update (GlobeNewswire) -5.25%
May-02-22 07:00AM	Talaris Therapeutics Announces Upcoming Presentations at American Transplant Congress (GlobeNewswire)
Apr-28-22 11:45AM	10 Best Stocks Under $20 According to Billionaire Andreas Halvorsens Viking Global (Insider Monkey)
Apr-06-22 04:01PM	Talaris Therapeutics Presents Data on COVID-19 Outcomes Among Kidney Transplant Patients Treated with FCR001 (GlobeNewswire)
Mar-22-22 04:01PM	Talaris Therapeutics to Participate at Two Upcoming Investor Conferences (GlobeNewswire) +5.50%
Mar-17-22 04:01PM	Talaris Therapeutics Announces Fourth Quarter and Year-End Financial Results (GlobeNewswire)
Feb-11-22 07:00AM	Talaris Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire) -9.18%
Feb-08-22 01:32PM	We're Hopeful That Talaris Therapeutics (NASDAQ:TALS) Will Use Its Cash Wisely (Simply Wall St.)
Jan-31-22 09:38AM	Altium Wealth Management LLC Buys Vanguard FTSE Emerging Markets ETF, Invesco Variable Rate ... (GuruFocus.com)
Jan-06-22 07:00AM	Talaris Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-04-22 07:00AM	Talaris Therapeutics to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference (GlobeNewswire)
Dec-20-21 07:00AM	Talaris Therapeutics Announces Addition to the Nasdaq Biotechnology Index (GlobeNewswire) +17.30%
Dec-14-21 07:00AM	Talaris Therapeutics Presents High-Resolution Analysis of HLA Mismatching in Phase 2 Trial in Living Donor Kidney Transplant (GlobeNewswire)
Nov-30-21 07:00AM	Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Individuals with a Severe Form of Scleroderma (GlobeNewswire)
Nov-12-21 07:00AM	Talaris Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Nov-08-21 07:00AM	Talaris Therapeutics to Participate at Three Upcoming Virtual Investor Conferences (GlobeNewswire)
Nov-04-21 06:00AM	Talaris Therapeutics Provides First FREEDOM-1 Phase 3 Clinical Update and Presents Additional Phase 2 Data and Analyses at American Society of Nephrology Meeting (GlobeNewswire)
Oct-29-21 07:00AM	Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Delayed Tolerance Induction (GlobeNewswire) +7.24%
Oct-28-21 04:36PM	Talaris Therapeutics Announces Upcoming Presentations and Investor Conference Call During American Society of Nephrology Meeting (GlobeNewswire)
Sep-02-21 07:00AM	Talaris Therapeutics to Participate at Two Upcoming Virtual Investor Conferences (GlobeNewswire)
Aug-12-21 07:00AM	Talaris Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Aug-10-21 08:10AM	Here's What Talaris Therapeutics, Inc.'s (NASDAQ:TALS) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Jun-14-21 04:01PM	Talaris Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Jun-03-21 07:00AM	Talaris Therapeutics Announces Upcoming Presentations on FCR001 at the Virtual 2021 American Transplant Congress (GlobeNewswire)
May-11-21 04:01PM	Talaris Therapeutics Announces Closing of Initial Public Offering (GlobeNewswire) -7.26%
May-06-21 09:53PM	Talaris Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. The firm offers TOUR006, an anti-IL-6 antibody that exhibits differentiated properties including high binding affinity to IL-6 and a naturally long half-life. It also plans to develop TOUR006 in thyroid eye disease and atherosclerotic cardiovascular disease. The company was founded by Sandeep Kulkarni on September 17, 2021 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kulkarni Sandeep Chidambar	CEO	Nov 17	Buy	16.99	4,000	67,960	729,735	Nov 20 06:15 PM
Thiara Parvinder	Director	Nov 17	Buy	17.31	1,000	17,310	83,782	Nov 20 06:14 PM
Castelein Caley	Director	Oct 27	Buy	14.55	15,800	229,890	516,519	Oct 27 05:43 PM
Kulkarni Sandeep Chidambar	CEO	Oct 26	Buy	12.25	5,000	61,250	725,735	Oct 26 05:34 PM
Castelein Caley	Director	Oct 25	Buy	12.07	4,200	50,694	500,719	Oct 27 05:43 PM
Thiara Parvinder	Director	Oct 25	Buy	12.12	2,000	24,240	82,782	Oct 26 04:46 PM
KANTOFF AARON	Director	Oct 24	Buy	11.86	7,500	88,950	45,391	Oct 26 05:00 PM
Thiara Parvinder	Director	Oct 24	Buy	10.66	5,000	53,300	80,782	Oct 26 04:46 PM
Kulkarni Sandeep Chidambar	CEO	Oct 24	Buy	10.68	4,650	49,662	720,735	Oct 26 05:34 PM
Ildstad Suzanne	Director	Jun 14	Sale	2.49	12,942	32,244	3,771,392	Jun 14 06:58 PM
Ildstad Suzanne	Director	Jun 13	Sale	2.56	14,208	36,338	3,784,334	Jun 14 06:58 PM
Ildstad Suzanne	Director	Jun 12	Sale	2.59	16,870	43,725	3,798,542	Jun 14 06:58 PM
Ildstad Suzanne	Director	Jun 09	Sale	2.46	25,419	62,637	3,815,412	Jun 09 05:41 PM
Ildstad Suzanne	Director	Jun 08	Sale	2.48	40,642	100,772	3,840,831	Jun 09 05:41 PM
Ildstad Suzanne	Director	Jun 07	Sale	2.39	75,001	179,095	3,881,473	Jun 09 05:41 PM
Ildstad Suzanne	Director	Jun 06	Sale	2.53	25,549	64,596	2,756,474	Jun 07 06:24 PM
Ildstad Suzanne	Director	Jun 05	Sale	2.52	7,841	19,755	2,782,023	Jun 07 06:24 PM
Ildstad Suzanne	Director	Jun 02	Sale	2.50	15,818	39,616	2,789,864	Jun 05 04:21 PM
Ildstad Suzanne	Director	Jun 01	Sale	2.56	15,713	40,177	2,805,682	Jun 05 04:21 PM
Ildstad Suzanne	Director	Apr 21	Sale	2.35	15,004	35,231	2,821,395	Apr 25 05:50 PM
Ildstad Suzanne	Director	Apr 20	Sale	2.33	46,990	109,313	2,836,399	Apr 21 07:57 AM
Ildstad Suzanne	Director	Apr 19	Sale	2.16	21,753	47,056	2,883,389	Apr 21 07:57 AM
Ildstad Suzanne	Director	Apr 18	Sale	2.15	49,211	105,804	2,905,142	Apr 19 09:22 AM
Ildstad Suzanne	Director	Apr 17	Sale	2.14	99,771	213,530	2,954,353	Apr 19 09:22 AM
Ildstad Suzanne	Director	Mar 17	Sale	2.06	10,436	21,543	3,054,124	Mar 20 04:36 PM
Ildstad Suzanne	Director	Mar 03	Sale	2.06	6,806	13,992	3,064,560	Mar 07 04:58 PM
Ildstad Suzanne	Director	Mar 01	Sale	2.05	29	59	3,071,366	Mar 02 05:26 PM
Ildstad Suzanne	Director	Feb 21	Sale	2.05	3,500	7,185	3,071,395	Feb 23 05:01 PM
Ildstad Suzanne	Director	Feb 17	Sale	2.05	3,612	7,406	3,074,895	Feb 21 11:16 AM
Ildstad Suzanne	Director	Feb 16	Sale	2.06	2,939	6,040	3,078,507	Feb 21 11:16 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TRML

Tourmaline Bio Inc

Upgrade your FINVIZ experience